News | July 22, 2023
Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin
Good momentum in commercial CDMO business
Good momentum in commercial CDMO business
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
The PP-based top and bottom webs are manufactured in a unique coextrusion process
SÜDPACK is setting standards in terms of both performance and sustainability
Subscribe To Our Newsletter & Stay Updated
